MedTrace Logo

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

NCT00487799 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2009-07-20

No results posted yet for this study

Summary

To determine the maximum tolerated dose (MTD) of ularitide in the treatment of subjects hospitalized with symptomatic acute decompensated heart failure (ADHF).

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

Ularitide

Sponsors & Collaborators

  • Facet Biotech

    lead INDUSTRY

Principal Investigators

  • William Cotts, MD · Feinberg School of Medicine, Northwestern Univ.

  • Gregory Ewald, MD · Washington University School of Medicine

  • Daniel Fuleihan, MD · Cardiovascular Specialists PC dba New York Heart Ctr

  • Barry Greenberg, MD · UCSD Medical Center

  • Darshak Karia, MD · Albert Einstein Medical Center

  • Elie Korban, MD · Kore Cardiovascular Research Institute

  • Richard Nowak, MD · Henry Ford Health System

  • Nirav Y. Raval, MD · The Atlanta Cardiology Group, PC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00487799 on ClinicalTrials.gov